{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-006852","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.063375+00:00","generated_at":"2026-05-22T05:27:06.096071+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Xilio reports Q1 net loss $13.3M, cash $89.1M; AbbVie deal provides $52M upfront","bullets":["Net loss $13.3M for Q1 2025, vs $17.2M Q1 2024.","Cash $89.1M as of Mar 31, 2025, up from $55.3M at Dec 31, 2024, driven by $52M AbbVie upfront.","R&D expenses $8.3M (down from $10.4M); G&A $8.5M (up from $6.1M) year-over-year.","Updated Phase 2 data for vilastobart + atezolizumab in MSS CRC to be presented at ASCO 2025 (abstract 3553).","First development candidates for masked T cell engagers (PSMA, CLDN18.2, STEAP1) expected H2 2025–H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-006852","json":"https://secwatch.observer/filing/0001558370-25-006852.json","markdown":"https://secwatch.observer/filing/0001558370-25-006852.md","text":"https://secwatch.observer/filing/0001558370-25-006852.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000155837025006852/0001558370-25-006852-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000155837025006852/xlo-20250508x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T05:27:06.096071+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}